Strong smell of burnt fingers (down 10%) or is it a smell of whisky or similar as a result of short term profits being toasted (ie: A quick relief slug of the strong stuff)
Thoughts on the back of a stamp? |
PU
You'll have plenty of time, I'm sure there won't be a rush of great contracts and if there's a rush of pi's pushing the price up, the results for quite a while will give a drop to buy into if you think real progress is possible.
If it does end up as a nice recurring revenue business based on continuous patient expansion, it won't really matter if you buy at 80p or 200p. The price will go up significantly in a few years time.
Growing recurring revenue is the holy grail and way better than capital based contracts. |
Must confess chickened out - Gut feel too fast up possible great revenue - The operative word being "possible" Will I kick myself in 6 months time? At least head now above water, with Dry Powder available for the 30th - |
Sorry to hear that LR2. Get well soon.
I caught a stinking cold over here in Spain and have a badminton tournament this weekend in Ronda. It's a place I always wanted to visit so an early knockout will allow more time for sightseeing lol.
So will young Tom now prise open his purse? |
Not too excited yet, as even with contracts (which I suspect won't have a quoted value because the payments are effectively performance-based), the whole thing will now be totally dependent on clinicians adopting Bleepa, not on a fixed contract.
I guess we'll find out soon whether the obstacle has been financial or willingness to adopt and change processes (or poor selling plus TO not having significant contacts at the right level). The partner Moorhouse apparently has. |
Yes, very pleased to read the news today. |
Sorry to hear that. Well at least this rise should cheer you up a little. |
I'm here Ged, just catching up. Not quite well at the moment. Got a lot of mucus on my lungs and feeling sorry for myself. |
Well if past teasing is anything to go by then no.
But if for once he delivers then maybe not today but I can see multiples of that price.
Now the news is out I wonder if he'll actually buy some shares.
And where is LR2? Hope his sister is OK. |
My last sell in these was at 68! Will I regret that today? |
Not complaining about seeing a rise this morning just very surprised that it's happened after all the empty promises of the last few years.
Is there anywhere in that announcement that states FDBK has been awarded anything? But they do believe or so they tell us.
"Company believes that an indicative ICB contract could generate over c. £2m per annum for Feedback under the ERF mechanism (assuming 66k patients per annum and that ERF rolls forward on an un-capped basis annually). ERF currently runs until 31st March 2025 but the Company believes, following central conversations, that the funding may be renewed in subsequent financial years to continue to support waitlist reduction."
Let's see the contracts!
You could be right Ducatiman.
The day is full of surprises - Yump is optimistic for a minute or two! |
As of August 2024, there were 7.64 million cases on the NHS waiting list, which is about 6.33 million individual patients. |
Putting on my most optimistic hat…
Assuming the funding continues, as a result of justified savings because of waiting list reductions, Feedback could end up being paid increasing repeating revenue for a very long time. |
Was adding bits to my post while you posted the crux of the matter ! |
Placing incoming no doubt. |
 I will have to re-read it though !
This bit is hidden in there:
“ the more activity delivered and diversions achieved the more an ICB will be reimbursed”
So the money appears to FOLLOW the activity. ie. Feedback provide the service and then get paid later, depending on no. of patients.
That would be very good for securing repeat revenues IF the throughput is sufficient, but it appears to require up front spend from feedback.
Existing contracts presumably will be moved or renewed on that basis, which takes them out of annual renewal capital spend and potential risk of being cut. No FDBK spend involved there hopefully.
Although this new funding runs out in March 2025.
If these new fangled contracts with a new ICB or trust don’t have a capital element, then Feedback is going to have to fund them with its own capital initially. The contracts may have zero committed value, with just a per patient clause.
So the risk is all transferred to Feedback and success depends on whether clinicians buy into it or not.
Lots of words in the RNS, but not the ones that matter to shareholders. I suspect the next step may be a series of announcements of “contractsR21; closely followed by a placing.
The implementation is clearly not going to fund itself. |
yump - Thanks - So maybe is the operative word. |
Sort of good news - perhaps.
So ring fenced and diverted capital budgets are supposedly an obstacle. Now there is a fund in revenue spend for diverting patients away from normal outpatient process.
That doesn’t answer the question of how many trusts are interested but stuck with the capital spend problem.
That is what I want to know. We have never been told that crucial information.
It also doesn’t cover the overall process of implementing Bleepa in a location, because its per-patient funding.
Can a trust get advance funding for a prospective number of patients, or does FDBK have to carry the implementaion spend/effort before any cash is forthcoming - and that depends on patient flow. So is there a contract committment from a trust ? Without it FDBK will be like a charity and so will shareholders.
The fact that they need an implementation partner makes me think they have been useless in getting even committment in principle from more tham a handful of trusts. |
Can anyone explain today's rns in plain language? Sounds good but? |
No comment |
yump - Nice one - With inside knowledge I understand the registered name of your new enterprise may be
"South Sea Bubbles" |
Would anyone like to know the total addressable market for my new social media add-on ? I’m afraid I will only be able to divulge information like that to investors putting at least £5000 up.
(Small print: There is no guarantee that anyone I try to address will listen to anything) |
LR2, total addressable market = bullsh1t. |
Anyone noticed the changes to the Investors page of Feedback Medical? The total addressable markets information is a good reminder. |
Thanks LR2!
I notice Sectra and Palantir are in that list. Both companies have been mentioned in this thread. Sectra in particular is notable since it's the PACs system used in the NCA. Bleepa obviously complements that PACS system.
Now how much of the £2B will be set aside for Feedback Medical?
About time something was awarded by Guys. After all it is the home of Feedback I seem to recall. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
